Wednesday, July 15 2020
TherapeuticsMD Inc. (TXMD)
Expanded Patient Access of Annovera
(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Expanding access to Annovera. TherapeuticsMD announced expansion of agreement with Nurx, the largest online practice for women’s health. Under this arrangement, Nurx will expand access to 300,000 patients across the country to TherapeuticsMD’s annual birth control ring Annovera.
Meaningful development. Annovera net sales were $2.3 million in Q1 2020, the patient demand doubled compared to Q4 2019. In our opinion, Annovera’s access to Nurx patients will generate meaningful revenue for the company, in spite of Covid-19’s halt on …
Click to get the full report
This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.